Q4 EPS Estimate for Hims & Hers Health Boosted by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Leerink Partnrs lifted their Q4 2024 earnings estimates for Hims & Hers Health in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.11 per share for the quarter, up from their previous forecast of $0.07. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q1 2025 earnings at $0.10 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.16 EPS, FY2026 earnings at $0.67 EPS and FY2027 earnings at $0.99 EPS.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) earnings per share. The business’s quarterly revenue was up 77.1% compared to the same quarter last year.

A number of other equities analysts have also recently issued reports on the company. TD Cowen increased their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Piper Sandler restated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday. Bank of America lifted their price target on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Truist Financial increased their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and a consensus target price of $20.71.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $20.64 on Wednesday. The stock’s 50-day moving average is $18.10 and its 200 day moving average is $18.19. Hims & Hers Health has a one year low of $6.23 and a one year high of $25.74. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 258.03 and a beta of 1.06.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the transaction, the insider now owns 176,952 shares in the company, valued at $2,919,708. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Michael Chi sold 7,500 shares of the business’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $22.20, for a total transaction of $166,500.00. Following the transaction, the insider now directly owns 193,980 shares in the company, valued at approximately $4,306,356. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 650,659 shares of company stock valued at $11,712,198. Corporate insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Carnegie Investment Counsel purchased a new stake in shares of Hims & Hers Health during the third quarter valued at approximately $5,531,000. International Assets Investment Management LLC purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $6,790,000. Sei Investments Co. raised its stake in shares of Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares during the period. Quantbot Technologies LP boosted its holdings in shares of Hims & Hers Health by 3,444.9% in the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after buying an additional 208,621 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after buying an additional 328,142 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.